Navigation Links
Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management

Physician's office system for measuring airway inflammation poised to

transform asthma management for improved control.

MENLO PARK, Calif., March 17 /PRNewswire/ -- Apieron, Inc. ( announced today that the Insight eNO system has received clearance to market by the U.S. Food and Drug Administration.

The Insight eNO system measures exhaled nitric oxide (eNO), which is a well-established indicator of airway inflammation and asthma control. The Insight system is a highly accurate device, expressly designed for the physician's office. It is non-invasive, safe, easy to use, and provides results in less than a minute. Apieron's unique biosensor detects trace amounts of nitric oxide molecules in a single human breath utilizing a proprietary technology. Current methods and techniques used to diagnose, monitor and treat asthma are costly, time-consuming and cumbersome. Physician office measurement of eNO is a much-awaited breakthrough in medical technology that provides physicians with a reliable tool to measure their patients' respiratory inflammation better than ever before. Measurement of eNO has also been shown to optimize medication therapy and improve compliance among patients with asthma.

William Berger, M.D., Clinical Professor of Pediatrics, University of California, Irvine, and Mission Viejo Medical Center, Mission Viejo, California, stated, "In clinical studies with the Apieron Insight eNO monitor, I found the ability to easily and accurately measure eNO in the physician's office to be a major advancement in my care for patients with persistent asthma."

It is estimated that more than 20 million people in the U.S. suffer from asthma, making it one of the most common and costly of all diseases. In fact, every day in America 40,000 people miss school or work due to asthma and 5,000 people go to the emergency room due to an asthma attack. One-quarter of all emergency room visits are asthma related and asthma is the most common chronic childhood disease.

"We are pleased to offer physicians and their patients a reliable, accurate and affordable asthma measurement and management device," said Rich Lotti, President and CEO of Apieron, Inc. "We believe this product will improve the standard of care for patients with asthma enabling physicians to optimize medical therapy for each patient."

"The availability of simple to use, accurate, and economically feasible eNO measurement devices now enables physicians to intelligently assess and manage the key pathologic feature of asthma, airway inflammation," said Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU School of Medicine, Shreveport, Louisiana. "Prior to the availability to measure eNO, assessing and managing airway inflammation was, for all practical purposes, little more than a guess! The ability to measure eNO in the physician's office is 'one giant step' in the care of adults and children with asthma."

The Insight eNO system includes a small desktop monitor with an easy-to- read display, trend analysis capabilities and a user-friendly interface. The system uses disposable, single-use sensors to measure nitric oxide accurately and non-invasively in less than a minute. Disposable, single-use breath tubes make it hygienic and convenient for the user to exhale into the device. Patient data can be stored and maintained in unique patient cards for trend analysis or downloaded to a printer for insurers' and patients' files.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.

Refer Questions to:

Holly McGarraugh

Apieron, Inc.


SOURCE Apieron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):